Recent Finacing
Recent Raise
Nephraegis Therapeutics develops NPH-022, an EET-pathway epoxyeicosatrienoic-related small molecule optimized for pharmacokinetics, conducting preclinical efficacy/safety studies and preparing IND and clinical development for acute kidney injury.
